Surf Therapeutics, a clinical-stage neuro-immunomodulation company developing non-invasive ultrasound therapy for chronic inflammatory diseases, is announcing the start of an Early Feasibility Study evaluating its investigational ultrasound device in people living with rheumatoid arthritis. The study is designed to assess a non-invasive approach to activate a neural pathway that triggers a robust anti-inflammatory response, without
News
Recent Stories
Cadwell and Medical Informatics Corp. Announce Partnership to Bring Neurodiagnostic Data into Clinical Intelligence Ecosystem
Cadwell, a global leader in neurodiagnostic and monitoring solutions, and Medical Informatics Corp (MIC), creators of the Sickbay Clinical Platform, today announced a strategic partnership that aims to bring a new standard of integrated data and monitoring to hospitals. As part of the agreement, Cadwell systems will be the first neurodiagnostic product integrated with Sickbay’s
Motif Neurotech Launches Patient Registry for Future Research Opportunities
Motif Neurotech, a brain-computer interface (BCI) company developing technologies for mental health, today announced that its patient registry is now live and accepting submissions from individuals with treatment-resistant depression (TRD) who may be interested in learning about potential future research opportunities. The registry will collect contact information from interested individuals to gauge interest in future
Fisher-Titus Medical Center and Luma Health Partner to Improve Healthcare Access for Patients in Northern Ohio
With consumer-grade self-scheduling, waitlist offers, and more, patients have easier access to world-class care close to home. Fisher-Titus Medical Center, a leading local health system offering the full continuum of care services to more than 70,000 patients in northern Ohio, deployed the Luma Health platform across 17 departments and multiple service lines to provide more
March Biosciences Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for MB-105 in Relapsed/Refractory CD5-Positive T-Cell Lymphoma
March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to MB-105, the Company’s first-in-class autologous CD5-targeted CAR-T cell therapy, in development for relapsed/refractory CD5-positive T-cell lymphoma. The RMAT designation was granted
6 female-founded startups shaping the Houston innovation ecosystem
This article from InnovationMap highlights the finalists for the 2025 Houston Innovation Awards, celebrating women-led startups driving impact across Houston’s innovation ecosystem, including March Biosciences, a TMC Venture Fund portfolio company, and Bairitone Health, a spinout from TMC’s Biodesign program, both recognized for their groundbreaking work in health technology and cancer therapeutics.
Houston digital health platform Koda closes $7 million funding round
Houston-based Koda Health, a digital advance care planning company born out of TMC’s Biodesign Fellowship, has closed an oversubscribed $7 million Series A round led by Evidenced to scale its operations and expand its national reach. The funding follows a year of major growth and integrations, positioning Koda to bring goal-aligned care to millions more